La chaîne d'options affiche les données clés des options sur actions de OptimizeRx à différents prix d'exercice et dates d'expiration. Les traders utilisent ces informations pour analyser les transactions potentielles et évaluer le sentiment du marché pour OptimizeRx..

OptimizeRx (NASDAQ:OPRX) Stock, Chaîne d'Options

OPTIMIZERX CORP

OptimizeRx

OptimizeRx Corp is engaged in the healthcare market in the United States. It provides digital health messaging via electronic health records, providing a direct channel for pharmaceutical companies to communicate with healthcare providers and patients. The cloud-based solution supports patient adherence to medications by providing real-time access to financial assistance, prior authorization, education, and clinical information. Its product offerings are Financial Messaging, Brand and Clinical Messaging, Brand Support, and Patient Engagement.

OptimizeRx Corp

News

OPRX

OptimizeRx Appoints CEO Steve Silvestro To Board Of Directors To Strengthen Leadership And Advance Strategic Growth Plans

Strategic Collaboration Brings Precision Micro-Neighborhood Targeting Healthcare Consumer Audiences to Linear and Connected TV

OptimizeRx And Simulmedia Join Forces To Enable Real-Time, Data-Driven TV Advertising For Life Sciences With Privacy-Forward Audience Targeting

Stifel analyst David Grossman maintains OptimizeRx (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OPRX#NASDAQ">OPRX</a>) with a Buy and raises the price target from $12.5 to $16.

Price Target

Analyst Ratings

Stifel Maintains Buy on OptimizeRx, Raises Price Target to $16

Rumors

Trading Ideas

Watching OptimizeRx; Hearing Zacks Homerun Newsletter Picks Stock

<h3>Gainers</h3>
<ul>
<li>Biodesix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BDSX#NASDAQ">BDSX</a>) stock moved upwards by 39.5% to $0.38 during Tuesday's after-market session. The company's market cap stands at $55.3 million. </li>
<li>Petros Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PTPI#NASDAQ">PTPI</a>) stock rose 26.37% to $0.16. The company's, Q1 earnings came out 3 days ago. </li>
<li>MetaVia (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MTVA#NASDAQ">MTVA</a>) stock rose 15.6% to $0.81. The market value of their outstanding shares is at $8.2 million. As per the press release, Q1 earnings came out 4 days ago. </li>
<li>CEL-SCI (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/CVM#AMEX">CVM</a>) stock rose 9.8% to $5.61. The market value of their outstanding shares is at $510.8 million. The company's, Q2 earnings came out 3 days ago. </li>
<li>OneMedNet (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ONMD#NASDAQ">ONMD</a>) stock rose 7.23% to $0.44. The market value of their outstanding shares is at $12.1 million. </li>
<li>VolitionRX (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/VNRX#AMEX">VNRX</a>) stock increased by 6.7% to $0.52. The market value of their outstanding shares is at $53.9 million. As per the news, the Q1 earnings report came out 3 days ago. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Universe Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UPC#NASDAQ">UPC</a>) shares fell 9.0% to $5.49 during Tuesday's after-market session. The market value of their outstanding shares is at $83.5 million. </li>
<li>HeartSciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HSCS#NASDAQ">HSCS</a>) shares declined by 6.46% to $4.2. The company's market cap stands at $4.5 million. </li>
<li>OptimizeRx (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OPRX#NASDAQ">OPRX</a>) stock fell 6.21% to $11.18. The company's market cap stands at $206.7 million. </li>
<li>HilleVax (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HLVX#NASDAQ">HLVX</a>) stock declined by 5.95% to $1.9. The company's market cap stands at $95.1 million. </li>
<li>Intensity Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INTS#NASDAQ">INTS</a>) shares decreased by 5.94% to $0.39. The company's market cap stands at $7.1 million. </li>
<li>Xtant Medical Hldgs (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/XTNT#AMEX">XTNT</a>) stock decreased by 5.77% to $0.66. The market value of their outstanding shares is at $92.1 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Movers

BDSX

HLVX

HSCS

INTS

MTVA

ONMD

PTPI

VNRX

XTNT

12 Health Care Stocks Moving In Tuesday's After-Market Session

Stifel analyst David Grossman maintains OptimizeRx (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OPRX#NASDAQ">OPRX</a>) with a Buy and raises the price target from $8 to $12.5.

Stifel Maintains Buy on OptimizeRx, Raises Price Target to $12.5

JMP Securities analyst Constantine Davides maintains OptimizeRx (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OPRX#NASDAQ">OPRX</a>) with a Market Outperform and raises the price target from $11 to $14.

JMP Securities Maintains Market Outperform on OptimizeRx, Raises Price Target to $14

WIIM

OptimizeRx shares are trading higher after the company reported better-than-expected Q1 financial results and raised its FY25 sales guidance with its midpoint above estimates.

COIN: 10% &#x7C; <a href="https://www.benzinga.com//node/45362657">Coinbase Global shares are trading higher it was announced that the company will join the S&amp;P 500, effective before the opening of trading on Monday, May 19.</a>
&nbsp;
OPRX: 24% &#x7C; <a href="https://www.benzinga.com//node/45360714">OptimizeRx shares are trading higher after the company reported better-than-expected Q1 financial results and raised its FY25 sale guidance with its midpoint above estimates.</a>
&nbsp;
CNSP: 160% &#x7C; <a href="https://www.benzinga.com//node/45371340">CNS Pharmaceuticals Announces Transfer Of Orphan Drug Designation For TPI 287 From Cortice Biosciences, Inc.</a>

CNSP

COIN

Market-Moving News for May 13th

U.S. stock futures fell on Tuesday after a stellar rally on Monday. Futures of major benchmark indices were trading lower in premarket.
Tech, consumer discretionary, and communication services led Monday&#8217;s rally as stocks surged on the<a href="https://www.benzinga.com/markets/equities/25/05/45341884/apple-amazon-nvidia-rise-in-monday-premarket-as-us-china-agree-to-90-day-tariff-truce-neither-side-wants-a-decoupling"> tariff truce</a> with China. 
President Donald Trump <a href="https://www.benzinga.com/general/health-care/25/05/45341590/trumps-drug-pricing-executive-order-could-rattle-pharma-stocksprice-cuts-up-to-80">signed an executive order</a> Monday, seeking to slash U.S. drug prices, fulfilling a social media pledge to achieve cuts of at least 59%. 
Meanwhile, the 10-year Treasury bond yielded 4.45% and the two-year bond was at 3.98%. The CME Group's FedWatch <a href="https://www.cmegroup.com/markets/interest-rates/cme-fedwatch-tool.html">tool</a>&#8216;s projections show markets pricing a 91.8% likelihood of the Federal Reserve keeping the current interest rates unchanged in its June meeting. 
<figure class="wp-block-table is-style-stripes"> 
<table class="has-fixed-layout">
<tbody>
<tr>
<td>Futures</td>
<td>Change (+/-)</td>
</tr>
<tr>
<td>Dow Jones</td>
<td>-0.20%</td>
</tr>
<tr>
<td>S&amp;P 500</td>
<td>-0.44%</td>
</tr>
<tr>
<td>Nasdaq 100</td>
<td>-0.54%</td>
</tr>
<tr>
<td>Russell 2000</td>
<td>-0.25%</td>
</tr>
</tbody>
</table>
</figure>
The SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) and Invesco QQQ Trust ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>), which track the S&amp;P 500 index and Nasdaq 100 index, respectively, were lower in premarket on Tuesday. The SPY was down 0.42% to $580.57, while the QQQ declined 0.50% to $505.29, according to <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a> data.
Cues From Last Session:
Information technology, consumer discretionary, and communication services sectors saw the biggest gains on Monday. The Dow Jones index soared over 1,100 points as the U.S. and China agreed to a <a href="https://www.benzinga.com/markets/equities/25/05/45341884/apple-amazon-nvidia-rise-in-monday-premarket-as-us-china-agree-to-90-day-tariff-truce-neither-side-wants-a-decoupling">90-day tariff truce</a>, effective May 14. 
This, along with the Trump administration&#8217;s progress to further formal trade talks amid growing economic pressures, fueled the market optimism.
However, this positive Monday followed a down week for major U.S. indices, with the S&amp;P 500, Nasdaq, and Dow all closing lower on Friday.
In stock-specific news, NRG Energy Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NRG#NYSE">NRG</a>) reported strong first-quarter results, while Kindly MD Inc.&#8216;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KDLY#NASDAQ">KDLY</a>) shares skyrocketed following a Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) treasury strategy merger.
Meanwhile, utility stocks moved against the broader market trend, closing lower.
After Monday, all the indices were out of the correction zone. The S&amp;P 500 index was down 4.93% from its record high of 6,147.43 points, scaled on Feb. 19. Dow Jones was 5.91% lower than its 52-week high of 45,073.63 points, and Nasdaq 100 was 6.09% lower than its previous high of 22,222.61 points.
The Dow Jones index declined 119 points or 0.29% to 41,249.38, whereas the S&amp;P 500 index fell 0.071% to 5,659.91. Nasdaq Composite ended 0.004% higher at 17,928.92, and the small-cap gauge, Russell 2000, dropped 0.16% to 2,023.07.
<figure class="wp-block-table is-style-stripes"> 
<table class="has-fixed-layout">
<tbody>
<tr>
<td>Index</td>
<td>Performance (+/-)</td>
<td>Value</td>
</tr>
<tr>
<td>Nasdaq Composite</td>
<td>4.35%</td>
<td>18,708.34</td>
</tr>
<tr>
<td>S&amp;P 500</td>
<td>3.26%</td>
<td>5,844.19</td>
</tr>
<tr>
<td>Dow Jones</td>
<td>2.81%</td>
<td>42,410.10</td>
</tr>
<tr>
<td>Russell 2000</td>
<td>3.42%</td>
<td>2,092.20</td>
</tr>
</tbody>
</table>
</figure>
Insights From Analysts:
Ryan Detrick from Carson Research highlighted in an X post that more than 55% of the S&amp;P 500 components made a new 20-day high on Monday.
According to the historical data presented by him, the S&amp;P 500 index ended 16.3% higher on average following days with such fresh 20-day highs. Out of the 30 times this has happened, the index has closed the year on a positive note 29 times.
&#8220;This is yet another clue the lows are likely in and better times are coming,&#8221; Detrick wrote in an X post.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">&gt;55% of the components in the S&amp;P 500 made a new 20-day high today. This is yet another clue the lows are likely in and better times are coming. Higher a year later 29 out of 30 times and up 16.3% on average. <a href="https://t.co/O0129ED0b9">pic.twitter.com/O0129ED0b9</a>
&mdash; Ryan Detrick, CMT (@RyanDetrick) <a href="https://twitter.com/RyanDetrick/status/1922139786845831186?ref_src=twsrc%5Etfw">May 13, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
The S&amp;P 500 index has a year-to-date performance low of 15.3%. Detrick highlighted that &#8220;Only three times in history has the S&amp;P 500 been down at least 15% YTD and moved back to positive by the end of the year.&#8221;
Despite having only three such instances historically, he added that 2025 could be the fourth such year.
&#8220;Call me crazy, but this year will be number four,&#8221; he said.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">Only three times in history has the S&amp;P 500 been down at least 15% YTD and moved back to positive by the end of the year. Call me crazy, but this year will be number four. <a href="https://t.co/JnVDNDgUKz">pic.twitter.com/JnVDNDgUKz</a>
&mdash; Ryan Detrick, CMT (@RyanDetrick) <a href="https://twitter.com/RyanDetrick/status/1922131292151337121?ref_src=twsrc%5Etfw">May 13, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
After the 90-day tariff pause between the U.S. and China, John Murillo, chief dealing officer of B2BROKER, a global fintech solutions provider, said that the news triggered an immediate positive market response. 
"Stocks and oil prices have rebounded – apparently, in reaction to the news, which can lead to lower costs for businesses and consumers," Murillo noted.
Despite the initial positive action following the announcement, Murillo emphasized the <a href="https://www.benzinga.com/government/regulations/25/05/45367206/sp-500-rallies-over-3-on-us-china-90-day-tariff-truce-but-experts-warn-it-doesnt-guarantee-a-complete-resolution-of-the-trade-war">temporary nature of the agreement</a>. "Now, while the 90-day pause is a big step towards easing tensions, it&#8217;s crucial to remember that it doesn&#8217;t guarantee a complete resolution of the trade war."
Meanwhile, Ed Yardeni, the President of Yardeni Research, has <a href="https://www.benzinga.com/25/05/45367861/ed-yardeni-revises-recession-odds-to-25-after-the-rally-bumps-sp-500-year-end-target-to-6500">lowered his U.S. recession probability</a> to 25% while raising his S&amp;P 500 target to 6,500 points for this year, following the trade deal with China. &#8212;
See Also: <a href="https://www.benzinga.com/money/how-to-trade-futures">How to Trade Futures </a>
Upcoming Economic Data
Here&#8217;s what investors will keep an eye on Tuesday:
<ul class="wp-block-list">
<li>April&#8217;s NFIB optimism index will be out by 6:00 a.m., whereas headline and core CPI data for April will be released by 8:30 a.m. ET.</li>
</ul>
Stocks In Focus:
<ul class="wp-block-list">
<li>Under Armour Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UAA#NYSE">UAA</a>) rose 1.45% in premarket on Tuesday as it is expected to report earnings before the opening bell. Analysts expect a quarterly earnings of 8 cents per share on the revenue of $1.16 billion.</li>
</ul>
<ul class="wp-block-list">
<li>Cyberark Software Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYBR#NASDAQ">CYBR</a>) was up 0.94% as Wall Street expects it to report earnings of 79 cents per share on revenue of $305.23 billion before the opening bell.</li>
</ul>
<ul class="wp-block-list">
<li>JD.com Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JD#NASDAQ">JD</a>) was 1% lower ahead of its earnings. Analysts expect earnings of $1.02 per share on revenue of $37.91 billion.</li>
</ul>
<ul class="wp-block-list">
<li>Acadia Healthcare Company Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACHC#NASDAQ">ACHC</a>) jumped 4.99% after reporting better-than-expected first-quarter financial results after the closing bell on Monday. The company posted adjusted earnings of 40 cents per share, with revenue of $770.50 million.</li>
</ul>
<ul class="wp-block-list">
<li>Coinbase Global Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COIN#NASDAQ">COIN</a>) surged 8.98% after the announcement that the company will join the S&amp;P 500, effective before the opening of trading on Monday, May 19.</li>
</ul>
<ul class="wp-block-list">
<li>Sangamo Therapeutics Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SGMO#NASDAQ">SGMO</a>) dropped 31.51% after reporting a quarterly loss of $0.14 per share versus the Zacks Consensus Estimate of a loss of $0.11.</li>
</ul>
<ul class="wp-block-list">
<li>Accelerate Diagnostics Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AXDX#NASDAQ">AXDX</a>) slumped 17.97% after it filed for Chapter 11 bankruptcy, leading to a delisting notice from Nasdaq due to non-compliance with listing requirements.</li>
</ul>
<ul class="wp-block-list">
<li>Microvision Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MVIS#NASDAQ">MVIS</a>) tumbled 13.22% after reporting a 40% decline in first-quarter revenue, falling to $0.6 million.</li>
</ul>
<ul class="wp-block-list">
<li>OPTIMIZERx Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OPRX#NASDAQ">OPRX</a>) zoomed 24.89% after it reported strong first-quarter financial results with revenue increasing 11% year-over-year to $21.9 million.</li>
</ul>
Commodities, Gold, And Global Equity Markets:
Crude oil futures were trading higher in the early New York session by 0.45% to hover around $62.23 per barrel.
Gold Spot US Dollar rose 0.61% to hover around $3,254.39 per ounce. Its last record high stood at $3,500.33 per ounce. The U.S. Dollar Index spot was lower by 0.18% at the 101.6080 level.
Asian markets ended on a mixed note on Tuesday as India's S&amp;P BSE Sensex and Hong Kong's Hang Seng index fell. While South Korea's Kospi, China&#8217;s CSI 300, Japan's Nikkei 225, and Australia's ASX 200 indices advanced. European markets were also mixed in early trade.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/25/05/45368511/china-to-us-goods-shipment-jump-after-90-day-tariff-postponement-a-big-backlog-is-looming">China To US Goods Shipment Jump After 90-Day Tariff Postponement: &#8216;A Big Backlog Is Looming&#8217;</a></li>
</ul>
Photo courtesy: Shutterstock

Equities

Markets

General

$BTC

ACHC

AXDX

CYBR

KDLY

MVIS

SGMO

US Stocks Likely To Open Lower After A Strong Rally: 'Lows Are Likely In And Better Times Are Coming,' Says Expert

<h3>Gainers</h3>
<ul>
<li>Xilio Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XLO#NASDAQ">XLO</a>) stock moved upwards by 28.6% to $0.94 during Monday's after-market session. The market value of their outstanding shares is at $48.6 million. As per the press release, Q1 earnings came out 2 days ago. </li>
<li>OptimizeRx (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OPRX#NASDAQ">OPRX</a>) shares rose 20.01% to $10.99. The market value of their outstanding shares is at $203.2 million. As per the press release, Q1 earnings came out today. </li>
<li>NewGenIvf Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NIVF#NASDAQ">NIVF</a>) shares moved upwards by 13.79% to $3.63. The company's market cap stands at $2.7 million. </li>
<li>Passage Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PASG#NASDAQ">PASG</a>) shares rose 10.28% to $0.34. The company's market cap stands at $21.1 million. </li>
<li>Harvard Bioscience (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HBIO#NASDAQ">HBIO</a>) shares increased by 10.13% to $0.39. The company's market cap stands at $17.1 million. As per the news, the Q1 earnings report came out today. </li>
<li>Aspire Biopharma Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASBP#NASDAQ">ASBP</a>) shares increased by 9.09% to $0.36. The market value of their outstanding shares is at $17.6 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Polyrizon (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLRZ#NASDAQ">PLRZ</a>) stock declined by 88.0% to $0.04 during Monday's after-market session. </li>
<li>Hepion Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HEPA#NASDAQ">HEPA</a>) stock decreased by 33.28% to $0.21. The company's market cap stands at $2.3 million. </li>
<li>Entero Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENTO#NASDAQ">ENTO</a>) shares fell 26.13% to $0.31. The company's market cap stands at $1.4 million. </li>
<li>Accelerate Diagnostics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AXDX#NASDAQ">AXDX</a>) stock declined by 25.43% to $0.1. The company's market cap stands at $2.5 million. </li>
<li>Sangamo Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SGMO#NASDAQ">SGMO</a>) stock fell 15.36% to $0.63. The company's market cap stands at $142.0 million. As per the news, the Q1 earnings report came out today. </li>
<li>Klotho Neurosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KLTO#NASDAQ">KLTO</a>) shares decreased by 10.06% to $0.16. The company's market cap stands at $4.4 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ASBP

ENTO

HBIO

HEPA

KLTO

NIVF

PASG

PLRZ

12 Health Care Stocks Moving In Monday's After-Market Session

OptimizeRx shares are trading higher after the company reported better-than-expected Q1 financial results and raised its FY25 sale guidance with its midpoint above estimates.

OptimizeRx (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OPRX#NASDAQ">OPRX</a>) raises FY2025 sales outlook from $100.00 million to $101.00 million-$106.00 million vs $101.26 million estimate.

Guidance

OptimizeRx Raises FY2025 Sales Guidance from $100.00M to $101.00M-$106.00M vs $101.26M Est

OptimizeRx (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OPRX#NASDAQ">OPRX</a>) reported quarterly earnings of $0.08 per share which beat the analyst consensus estimate of $(0.12) by 166.67 percent. This is a 172.73 percent increase over losses of $(0.11) per share from the same period last year. The company reported quarterly sales of $21.93 million which beat the analyst consensus estimate of $18.69 million by 17.35 percent. This is a 11.37 percent increase over sales of $19.69 million the same period last year.

Earnings

Earnings Beats

OptimizeRx Q1 Adj. EPS $0.08 Beats $(0.12) Estimate, Sales $21.93M Beat $18.69M Estimate

ACHR

ACNT

AGEN

AIRJ

ALLT

ALTI

AMBC

AMPY

APEI

AQST

ARCT

ARWR

ASRT

ASYS

AUPH

BATRA

BATRK

Mobile Infrastructure Corporation Common Stock

BEEP

BETR

Bakkt Holdings, Inc. Class A Common Stock

BKKT

BLDE

BLNK

CATX

CEPU

CHGG

CHRS

CLLS

CLPR

CMCL

CMPO

CNNE

CNTY

CPSS

CTMX

CTRI

CWCO

DOLE

EDIT

EXOD

FGEN

FOXA

FRPH

FTEK

FTRE

GAIA

GETY

GPRO

GRDN

HFFG

HNRG

IHRT

IMNN

INDI

ISPR

KBDC

KPTI

KSPI

LAND

LEGH

LINC

LSEA

LTBR

METC

Ramaco Resources, Inc. - Class B Common Stock

METCB

MFIC

MLNK

MLYS

MNDY

MODG

MRVI

MVST

NMRA

NOTE

NPWR

NRGV

NRXS

Earnings Scheduled For May 12, 2025

Offerings

OptimizeRX Corp Files For Mixed Shelf Of Up To $75M

<h3>Gainers</h3>
<ul>
<li>CervoMed (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRVO#NASDAQ">CRVO</a>) stock increased by 151.1% to $5.93 during Wednesday's regular session. The market value of their outstanding shares is at $48.9 million. </li>
<li>OptimizeRx (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OPRX#NASDAQ">OPRX</a>) shares rose 35.74% to $5.62. The company's market cap stands at $103.5 million. As per the press release, Q4 earnings came out today. </li>
<li>Healthcare Triangle (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HCTI#NASDAQ">HCTI</a>) shares increased by 26.86% to $0.41. The market value of their outstanding shares is at $2.6 million. </li>
<li>HeartSciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HSCS#NASDAQ">HSCS</a>) stock increased by 19.86% to $3.5. The market value of their outstanding shares is at $3.4 million. </li>
<li>Baird Medical Investment (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BDMD#NASDAQ">BDMD</a>) stock rose 18.18% to $5.46. The market value of their outstanding shares is at $198.5 million. </li>
<li>Shuttle Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SHPH#NASDAQ">SHPH</a>) shares moved upwards by 18.18% to $0.5. The market value of their outstanding shares is at $2.0 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Zynex (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZYXI#NASDAQ">ZYXI</a>) stock fell 53.9% to $3.23 during Wednesday's regular session. The market value of their outstanding shares is at $102.8 million. As per the news, the Q4 earnings report came out yesterday. </li>
<li>Hepion Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HEPA#NASDAQ">HEPA</a>) shares decreased by 40.6% to $0.05. </li>
<li>Syros Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SYRS#NASDAQ">SYRS</a>) stock decreased by 30.23% to $0.09. The company's market cap stands at $2.5 million. </li>
<li>Impact BioMedical (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/IBO#AMEX">IBO</a>) stock declined by 29.42% to $0.6. The company's market cap stands at $6.9 million. </li>
<li>Tenon Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TNON#NASDAQ">TNON</a>) shares fell 25.24% to $1.13. The market value of their outstanding shares is at $3.5 million. </li>
<li>Cutera (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CUTR#NASDAQ">CUTR</a>) shares declined by 18.54% to $0.09. The market value of their outstanding shares is at $1.7 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

BDMD

CRVO

CUTR

HCTI

SHPH

SYRS

TNON

ZYXI

12 Health Care Stocks Moving In Wednesday's Intraday Session

OPTIMIZERx Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OPRX#NASDAQ">OPRX</a>), a health care technology firm, reported on Wednesday fourth-quarter sales of $32.32 million, up 14% year-over-year, beating the <a href="https://www.benzinga.com/calendars/earnings" target="_blank" rel="noreferrer noopener">consensus of $30.36 million</a>.
The company reported adjusted EPS of 30 cents, beating the <a target="_blank" href="https://www.benzinga.com/general/health-care" rel="noreferrer noopener">analyst&#8217;s estimate of 27 cents</a>.
Full-year revenue increased 29% year-over-year, reaching $92.1 million. The company&#8217;s gross profit climbed 23% in the fourth quarter to $22 million, with full-year gross profit <a href="https://www.benzinga.com/pressreleases/25/03/g44272532/optimizerx-reports-strong-fourth-quarter-and-full-year-2024-financial-results" target="_blank" rel="noreferrer noopener">totaling $59.4 million</a>.
Adjusted EBITDA demonstrated significant growth, increasing 53% year-over-year in the fourth quarter to $8.8 million. For the full year, adjusted EBITDA reached $11.7 million.
OptimizeRx ended 2024 with $13.4 million in cash and cash equivalents, with net cash provided by operating activities totaling $4.9 million.
Also Read: <a target="_blank" href="https://www.benzinga.com/news/contracts/25/03/44277984/whats-going-on-with-baker-hughes-stock-today" rel="noreferrer noopener">What&#8217;s Going On With Baker Hughes Stock Today?</a>
&#8220;With the strong tailwinds we saw at the end of 2024 and into the start of 2025, we believe we are uniquely positioned to grow shareholder value by leveraging our industry leadership position in addressing pharma&#8217;s most critical commercial challenges: improving brand visibility in an increasingly digital healthcare environment, reducing script abandonment rates, enhancing interoperability at the point of care, and supporting the shift toward complex specialty medications,&#8221; OptimizeRx CEO Stephen L. Silvestro said.
Key performance indicators reflected the company&#8217;s strong relationships with major pharmaceutical manufacturers.
<ul>
<li>The top 20 pharmaceutical companies accounted for 64% of total revenue, with an average revenue per top manufacturer of $2.93 million, up from $2.4 million in 2023.</li>
<li>The company maintained a 100% penetration rate among these top pharmaceutical clients and improved its net revenue retention to 121%, compared to 105% in the prior year.</li>
</ul>
Guidance: OptimizeRx expects continued growth in 2025, forecasting revenue of at least $100 million versus a consensus of $99.65 million and an adjusted EBITDA of at least $12 million.
OPRX Price Action: OptimizeRx stock is up 40.78% at $5.83 at publication Wednesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/03/44275624/roche-further-boosts-its-obesity-pipeline-with-zealand-pharma-deal-worth-53-billion-for-weight-loss-drugs" target="_blank" rel="noreferrer noopener">Roche Further Boosts Obesity Pipeline With Zealand Pharma Deal Worth $5.3 Billion For Weight Loss Drugs</a></li>
</ul>
Photo: Shutterstock

Health Care

OptimizeRx Clocks Double-Digit Revenue Growth In Q4, Forecasts Sales Of At Least $100 Million

OptimizeRx Corporation Shares Resume Trading; Up 54%

OptimizeRx Shares Halted On Circuit Breaker To The Upside, Stock Now Up 53.1%

Management

Press Releases

OptimizeRx Corporation Appoints Stephen Silvestro as Chief Executive Officer

OptimizeRx Corporation Confirms Receipt of Notice of Director Nominations

OptimizeRx Reports Strong Fourth Quarter and Full Year 2024 Financial Results

OptimizeRx Corporation Announces Plan for Additional Board of Directors Refreshment

OptimizeRx Sets First Quarter 2025 Conference Call for May 12, 2025, at 4:30 p.m. ET

OptimizeRx Releases 2025 Environmental, Social, and Governance (ESG) Report

OptimizeRx Reports First Quarter 2025 Financial Results and Updates Fiscal Year 2025 Guidance

Comments

OptimizeRx

OptimizeRx (OPRX) Options

OptimizeRx (NASDAQ:OPRX) Stock, Chaîne d'Options

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL